Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Leerink Global Healthcare Conference 2017

16 slides from Synergy Pharmaceuticals's conference presentation, Feb 15, 2017

  1. Slide 1: Safe Harbor Statement

    Slide 1: Safe Harbor Statement

    SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subjec

  2. Slide 2: Key Investment Highlights

    Slide 2: Key Investment Highlights

    KEY INVESTMENT HIGHLIGHTS • • • Large market opportunity with ~45M U.S. adults with CIC/IBS-C Value of Rx constipation market grew nearly 150% in last 3 years Market expected to grow at double digit rates with increased treatment options, market education and awareness of gut health Attractive Marke

  3. Slide 3: GI Pipeline Well Diversified with Multiple Growth Opportunities

    Slide 3: GI Pipeline Well Diversified with Multiple Growth Opportunities

    GI PIPELINE WELL OPPORTUNITIES DIVERSIFIED WITH MULTIPLE GROWTH this quarter proof-of-concept Leerink Global Healthcare Conference I February 15, 2017 4 UROGUANYLIN ANALOG PHASE 1 PHASE 2 PHASE 3 NDA FILINGS MARKET STATUS TRULANCE (plecanatide) CIC Now FDA Approved IBS-C IBS-C sNDA filing expected D

  4. Slide 4: Trulance Commercial Opportunity

    Slide 4: Trulance Commercial Opportunity

    TRULANCE COMMERCIAL OPPORTUNITY 5

  5. Slide 5: Estimated Million U.S. Adults Suffer from CIC or IBS-C

    Slide 5: Estimated Million U.S. Adults Suffer from CIC or IBS-C

    ESTIMATED 45 MILLION U.S. SUFFER FROM CIC OR IBS-C ADULTS COMMON SYMPTOMS: Estimated U.S. Prevalence (in millions) • Constipation (< 3 bowel movements per week for > 3 months) Hard or lumpy stools Incomplete bowel movements Straining CIC/IBS-C • • • GERD Migraine • • • Abdominal pain Constipation In

  6. Slide 6: Limited Prescription Treatment Options for CIC and IBS-C

    Slide 6: Limited Prescription Treatment Options for CIC and IBS-C

    LIMITED PRESCRIPTION TREATMENT AND IBS-C AVAILABLE OPTIONS FOR CIC TYPICAL TREATMENT PROGRESSION Changes to Diet and Lifestyle (fiber, water intake, exercise) OTC Laxatives and Stool Softeners (Miralax®, Lactulose, etc.) Only 2 FDA Approved Products (Amitiza®, Linzess®) Leerink Global Healthcare Con

  7. Slide 7: New Entrants Are Growing the Market, Not Cannibalizing Existing Products

    Slide 7: New Entrants Are Growing the Market, Not Cannibalizing Existing Products

    NEW ENTRANTS ARE GROWING THE MARKET, NOT CANNIBALIZING EXISTING PRODUCTS ~ 4 MM 20,000 16,465 373 15,000 10,000 5,000 0 2013 2014 2015 2016 All Other Rx = Rx lactulose & Rx polyethylene glycol Source: IMS Health Incorporated, NPA Leerink Global Healthcare Conference I February 15, 2017 8 TRxs in Tho

  8. Slide 8: Value of the Prescription Constipation Market Has More Than Doubled Over Past 3 Years

    Slide 8: Value of the Prescription Constipation Market Has More Than Doubled Over Past 3 Years

    THE VALUE OF THE PRESCRIPTION CONSTIPATION MARKET HAS MORE THAN DOUBLED OVER THE PAST 3 YEARS + 148% $1,500 $1,000 $500 $0 2013 2014 2015 2016 All Other Rx = Rx lactulose & Rx polyethylene glycol Source: IMS Health Incorporated, NSP Leerink Global Healthcare Conference I February 15, 2017 9 US $ in

  9. Slide 9: Still an Untapped US Market Opportunity

    Slide 9: Still an Untapped US Market Opportunity

    STILL AN UNTAPPED US MARKET OPPORTUNITY FUTURE GROWTH DRIVERS ~ 45MM U.S. ADULTS WITH CIC / IBS-C • DTC campaigns continue to grow disease awareness • Growth in category with new IBS-D / OIC brands > 95% currently not treated with branded Rx therapies Branded Rx market serving < 5% • Increasing awar

  10. Slide 10: Trulance Commercial & Launch Readiness

    Slide 10: Trulance Commercial & Launch Readiness

    TRULANCE COMMERCIAL & LAUNCH READINESS 11

  11. Slide 11: Product Readiness: Supply on Track for Launch This Quarter

    Slide 11: Product Readiness: Supply on Track for Launch This Quarter

    PRODUCT QUARTER SUPPLY ON-TRACK FOR LAUNCH THIS Product Readiness Leerink Global Healthcare Conference I February 15, 2017 12 MAJOR INITIATIVES •Established robust supply chain process •Trade and sample stock ready for launch this quarter •Launching with 30-day blister pack

  12. Slide 12: Market and Trulance Brand Prepared for Launch

    Slide 12: Market and Trulance Brand Prepared for Launch

    MARKET AND TRULANCE BRAND PREPARED FOR LAUNCH Market / Brand Readiness WAC = Wholesale Acquisition Cost Leerink Global Healthcare Conference I February 15, 2017 13 MAJOR INITIATIVES •Finalized pricing strategy --launching at WAC price of $353.48 •Completed extensive market research with more than 2,

  13. Slide 13: Commercial Team with Significant GI Experience and Several Product Launches

    Slide 13: Commercial Team with Significant GI Experience and Several Product Launches

    COMMERCIAL TEAM WITH SIGNIFICANT GI EXPERIENCE AND SEVERAL PRODUCT LAUNCHES Organizational Readiness - Commercial • • Over 25 years of experience in pharma: Shire, J&J & IMS Health Expertise in business analytics, market research, forecasting, call plan deployment & commercial IT infrastructure Sign

  14. Slide 14: Experienced Sales and Market Access Team

    Slide 14: Experienced Sales and Market Access Team

    EXPERIENCED SALES AND MARKET ACCESS TEAM Organizational Readiness - Commercial • Synergy RBDs average over 11 years of management experience with over 10 years in relevant GI fields Hired from peer GI and PCP companies Regional Business Directors • • Implementing flexible and efficient hybrid sales

  15. Slide 15: Trulance and Synergy Are Well Positioned

    Slide 15: Trulance and Synergy Are Well Positioned

    TRULANCE AND SYNERGY ARE WELL POSITIONED ~ 45M US Adults with CIC/IBS-C Significant unmet need; multiple drivers for future growth Strong Product Profile Based on clinical data, MOA, and market research/customer insights Strong - Focused - Efficient Product Readiness, Market/Brand Readiness, Organiz

  16. Slide 16: Trulance and Synergy Are Well Positioned

    Slide 16: Trulance and Synergy Are Well Positioned

    TRULANCE AND SYNERGY ARE WELL POSITIONED Right Market Right Profile Right Strategy Right Team SYNERGY Leerink Global Healthcare Conference | February 15, 2017

Source: SEC EDGAR · 8-K filed Feb 15, 2017

More decks from Synergy Pharmaceuticals Inc